ERA, Congress

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

Published on 08/07/2025 at 18:04 | prnewswire.co.uk

ERA Congress United Kingdom United States of America France Germany Spain Sweden

en | boerse | 67983465 |